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AbsTrACT
Objectives to investigate whether observational 
studies of hIV and herpes simplex virus type 2 (hSV-2) 
infections have the capacity to assess the hIV/hSV-2 
epidemiological synergy.
Methods An individual-based Monte Carlo model 
was used to simulate hIV/hSV-2 epidemics in two 
scenarios: no hIV/hSV-2 biological interaction and hSV-2 
seropositivity enhancing hIV acquisition. Cross-sectional 
observational studies were simulated by sampling 
individuals from the population to assess resulting crude 
and adjusted ors of the hIV/hSV-2 association. Meta-
analyses were conducted to estimate the pooled mean 
ors. Impact of under-reporting of sexual behaviour and 
miscapture of high-risk individuals was assessed through 
sensitivity analyses.
results Assuming no hIV/hSV-2 biological interaction, 
the crude hIV/hSV-2 or ranged between 1.38 and 9.93, 
with a pooled mean of 6.45 (95% CI 5.81 to 7.17). 
Adjustment for the number of sexual partners over 
last year, over lifetime and for both partner numbers 
simultaneously reduced the mean or to 5.45 (95% CI 
4.90 to 6.06), 3.70 (95% CI 3.32 to 4.12) and 3.54 
(95% CI 3.17 to 3.94), respectively. Assuming hIV/hSV-
2 biological interaction, the crude or ranged between 
3.44 and 9.95, with a pooled mean of 8.05 (95% CI 
7.14 to 9.07). the adjustments reduced the mean or to 
7.00 (95% CI 6.21 to 7.90), 3.76 (95% CI 3.32 to 4.25) 
and 3.68 (95% CI 3.25 to 4.17), respectively. Under-
reporting of partners reduced the confounder-adjustment 
effects. Miscapture of high-risk individuals considerably 
lowered the estimated ors.
Conclusions It is difficult to control for sexual-
behaviour confounding in observational studies. 
the observed hIV/hSV-2 association appears more 
consistent with two infections sharing the same mode 
of transmission, rather than with hSV-2 enhancing hIV 
acquisition.
InTrOduCTIOn
The biological interactions and epidemiological 
synergy between HIV and herpes simplex virus type 
2 (HSV-2) infections have been intensely investi-
gated.1 There is ample observational evidence for 
a strong HIV/HSV-2 association, and that HSV-2 
enhances HIV acquisition.2–4 Mathematical models 
incorporating this synergy estimated that HSV-2 
has been a major contributor to the HIV epidemic 
in sub-Saharan Africa (SSA).1 5 
Nevertheless, HIV and HSV-2 share the same 
sexual mode of transmission and propagate on 
the same sexual networks. It is ‘natural’ for these 
two infections to be strongly associated regardless 
of any HIV/HSV-2 biological interaction. Obser-
vational studies attempted to control for this 
confounding factor by adjusting the measured asso-
ciations for sexual behaviour, often by controlling 
for the number of self-reported sexual partners.4 As 
adjusted associations were still positive and strong, 
this supported the existence of a biological interac-
tion, and consequently an epidemiological synergy, 
between these two infections.4 As most self-re-
ported sexual data are egocentric, network effects 
could not be adjusted for in these observational 
studies.
The difficulty of controlling for network effects, 
however, limits the validity of these observational 
studies. The risk of acquiring an STI depends 
not only on a person's behaviour, but also on the 
“ecology” of the person within the sexual network, 
including the partners and partners' partners 
behaviour, past and present.6–11 Sexual networks, 
therefore, play a critical role in determining STI 
patterns.6 8 12 For example, it has been hypothesised 
that concurrency is a main driver of the generalised 
HIV epidemics in SSA.13–15
Several clinical trials were conducted to target the 
HIV/HSV-2 epidemiological synergy, by suppressing 
HSV-2 reactivation to reduce HIV acquisition and 
transmission, but these trials reached negative 
outcomes.16–18 Different explanations have been 
advanced for these negative results, such as ineffec-
tive HSV-2 suppression, insufficient dose or therapy 
duration, and poor adherence.16–19 It is natural, 
however, to also question the very existence of 
this epidemiological synergy—that is, the observed 
HIV/HSV-2 association could be a spurious associ-
ation not reflecting a genuine biological effect; it 
arose from intrinsic biases in study design due to 
failure to adequately control for confounding by 
sexual behaviour.
Here we investigate two related questions: 
Can observational studies adequately control for 
confounding by sexual behaviour? Is the observed 
association consistent with an absence of epidemio-
logical synergy? We addressed these two questions 
through mathematical modelling by first simulating 
HIV/HSV-2 transmission in diverse sexual networks 
assuming no HIV/HSV-2 biological interaction. We 
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then simulated HIV/HSV-2 transmission assuming HIV/HSV-2 
biological interaction with an effect size as that reported in 
observational studies.2–4 Subsequently, we simulated the conduct 
and analysis of observational studies on the simulated epidemics, 
that is, we cross-sectionally sampled individuals from the popu-
lation and estimated sample associations by logistic regressions.
In light of known limitations to observational evidence, namely 
under-reporting of sexual behaviour and miscapture (under-
sampling) of high-risk individuals in surveys, we repeated our 
analyses factoring in these limitations. Our study thus furnishes 
a ‘microscopic’ assessment, from first principles, of one of the 
most controversial factors in HIV epidemiology.
METhOdOlOgy
We used a recently constructed individual-based Monte Carlo 
simulation model6 to simulate sex partnering, birth/death and 
HIV/HSV-2 transmission in a population. The model was applied 
in two scenarios. First, HIV/HSV-2 transmission was simu-
lated assuming no HIV/HSV-2 biological interaction. Second, 
HIV/HSV-2 transmission was simulated assuming that HSV-2 
seropositivity increases the risk of HIV acquisition by 2.5-fold—
the relative risk effect size as estimated from observational 
studies.2–4 In the latter scenario, we lowered the overall average 
level of sexual risk behaviour so that both scenarios had similar 
HIV prevalence levels. Accordingly, the second scenario can be 
seen as a ‘positive control’ of the first scenario.
The model was parameterised with representative natural 
history and transmission parameters,1 6 listed in online supple-
mentary table S1. Since observational studies suggest that the 
effect size of the HIV/HSV-2 association varies between popu-
lations, such as the general population versus high-risk popula-
tions,3 we assessed the association in diverse sexual networks to 
accommodate for potential variability in effect size by type of 
population/sexual network.
The sexual networks were simulated based on the range of 
population-based sexual behaviour data in SSA,20 as derived 
from 25 Demographic and Health Surveys (DHS) data.21 
Marital partnerships formed/dissolved at a rate derived from 
DHS current-marriage age-specific data.6 21 Non-marital part-
nerships formed/dissolved in unmarried (premarital sex) and 
married (extramarital sex) persons, but at different DHS-derived 
rates.6 20 Sexual behaviour parameters were sampled (randomly) 
from the empirical distributions20 to generate a diversity of 
sexual network statistics such as number-of-partners mean and 
variance, degree correlation, clustering coefficient, and concur-
rency—accommodating for variation by marital status and age.6
We simulated 100 HIV/HSV-2 epidemics on 100 different 
sexual networks, with initial population sizes of 2000, for each 
scenario—numbers sufficient to be representative of the diver-
sity of the (stochastic) epidemics we see for these two infections. 
Each simulation was seeded with 10 HIV/HSV-2 infections, and 
was run with a ‘burn-in’ time of 200 years to reach equilibrium. 
Although the model allows assessment of the HIV/HSV-2 asso-
ciation temporally and by epidemic phase, we only assessed 
the association at endemic equilibrium to control for potential 
temporal effects on the association.
We cross-sectionally sampled all individuals 15–65 years of 
age from each of the 100 simulated epidemics/populations. In 
each sample, we assessed the HIV/HSV-2 association. Different 
univariable and multivariable logistic regression analyses were 
conducted to calculate crude and adjusted ORs of HIV infec-
tion with HSV-2 seropositivity. The following independent 
predictors were selected a priori because of relevance to the 
research questions: number of sexual partners over the last year 
(continuous variable), number of lifetime partners (continuous 
variable), age (continuous variable) and marriage (categorical 
variable), in addition to HSV-2 serostatus (categorical variable). 
Different regression models were used to adjust for the number 
of sexual partners over the last year, number of lifetime partners, 
both numbers of partners, and both numbers of partners, age 
and marriage. The latter analysis was done to reflect common 
adjustment variables in observational studies.4 ORs of the 100 
simulated studies were pooled using a DerSimonian-Laird 
random-effects model to calculate pooled effects.
For sensitivity analyses, we repeated the above analyses for 
each scenario, but after reducing (randomly) the reported 
number of partners over the last year, for individuals with >1 
partners, by an average of 10%, 25% and 50%, to simulate 
under-reporting of sexual behaviour. We also repeated the above 
analyses, but after excluding individuals with the highest 10%, 
25% and 50% number of partners over the last year, to simulate 
miscapture of high-risk individuals.
rEsulTs
Table 1 shows the results of the regression analyses assuming 
no HIV/HSV-2 biological interaction. In the baseline scenario 
of no under-reporting and no miscapture, the crude OR ranged 
between 1.38 and 9.93, with a pooled mean of 6.45 (95% CI 
5.81 to 7.17). Adjustment for the number of partners over last 
year, over lifetime and for both numbers of partners reduced the 
mean OR to 5.45 (95% CI 4.90 to 6.06), 3.70 (95% CI 3.32 to 
4.12) and 3.54 (95% CI 3.17 to 3.94), respectively. Adjustment 
for age and marriage in addition to partner numbers yielded 
an OR of 4.93 (95% CI 4.41 to 5.52). The sensitivity anal-
yses assuming under-reporting and miscapture yielded similar 
patterns.
Table 2 shows the results of the regression analyses assuming 
increased HIV acquisition with HSV-2 seropositivity. In the base-
line scenario of no under-reporting and no miscapture, the crude 
OR was higher with a range of 3.44–9.95 and a pooled mean of 
8.05 (95% CI 7.14 to 9.07). Adjustment for the number of part-
ners over last year, over lifetime and for both numbers of part-
ners reduced the mean OR by larger margins than those with no 
HIV/HSV-2 biological interaction—the mean OR was reduced 
to 7.00 (95% CI 6.21 to 7.90), 3.76 (95% CI 3.32 to 4.25) and 
3.68 (95% CI 3.25 to 4.17), respectively. Adjustment for age 
and marriage in addition to partner numbers yielded an OR of 
4.71 (95% CI 4.15 to 5.35). The sensitivity analyses assuming 
under-reporting and miscapture yielded similar patterns.
Adjustments for the lifetime number of partners always had 
larger effects on the OR than those for the last-year number 
of partners (tables 1 and 2). The simultaneous adjustment for 
both numbers of partners resulted in a larger effect on the OR, 
although not much larger than that for only the lifetime number 
of partners. Under-reporting of partners reduced the adjustment 
effects for both numbers of partners. Miscapture of high-risk 
individuals considerably lowered the estimated ORs.
dIsCussIOn
Our results demonstrate the difficulty of adequately controlling 
for sexual-behaviour confounding. While the ORs were closer to 
1 after adjustment for numbers of partners, they remained well 
above 1 despite absence of any biological interaction in the first 
modelling scenario. The lifetime-partner-number adjustment 
was also more effective, probably because it captured better the 
exposure risk to both infections over lifetime.
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These findings highlight how HIV or HSV-2 exposure risk in 
a sexual network cannot be captured by simply numbers of part-
ners, but depends on an array of network properties, including 
variance of number of partners, concurrency and clustering 
/assortativeness.6 22
As expected, the ORs were larger in the positive-control analyses 
where HSV-2 seropositivity increased the risk of HIV acquisition 
(table 2). However, these ORs were not as large as one may have 
expected given the biological interaction. The adjustments for 
the sexual-behaviour confounding yielded also larger reductions 
in the ORs compared with the ‘null’ scenario of no interaction 
(table 2 vs table 1). These outcomes testify to the complexity of 
the HIV/HSV-2 overlapping epidemiology. AIDS mortality, for 
example, had a differential effect based on HSV-2 serostatus (with 
the higher risk of acquiring HIV for those HSV-2 seropositive), 
thereby lowering the values of the ORs.
Our results demonstrate how the ORs depend on complex 
interplays between the HIV/HSV-2 biological interaction, sexual 
behaviour and networking, HIV/HSV-2 background prevalence, 
demography, and AIDS mortality. This lack of a one-to-one corre-
spondence between ‘true’ and observed ORs further increases the 
challenge of disentangling a biological interaction between HIV 
and HSV-2 from methodological biases.
This study has limitations. Our findings could conceivably 
be dependent on our model. While we studied this association 
across a diversity of sexual networks and HIV/HSV-2 epidemics, 
other factors, not accounted for here, may also affect the epide-
miological observations, such as potential variation of this asso-
ciation by risk population, sex or biological route of exposure 
(eg, men who have sex with men versus heterosexual popula-
tions). Our results may not also explain the observed HIV/
HSV-2 synergy in serodiscordant couples.3 Having said so, the 
evidence from serodiscordant couples for an association appears 
inconclusive.3 Lastly, while our results cast doubt on an effect 
for HSV-2 on enhancing HIV acquisition, they do not strictly 
preclude an HSV-2 effect on enhancing HIV infectiousness.
In conclusion, can observational studies adequately control for 
confounding by sexual behaviour? Our findings demonstrate that 
it is challenging to assess the existence of an HIV/HSV-2 biological 
interaction in observational studies, as it is difficult (if not impos-
sible) to fully control for the sexual-behaviour confounding using 
egocentric partners’ data. Is the observed association consistent 
with an epidemiological synergy or confounding? The answer to 
this question remains unsettled, but our findings suggest that the 
empirically observed HIV/HSV-2 association appears to be more 
consistent with two infections sharing the same mode of trans-
mission—HSV-2’s effect on HIV acquisition may be weaker than 
thought, perhaps even absent.
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